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Abstract
Many and large dumps exist in our knowledge about Mycobacterium tuberculosis infection and disease in infants
and children. We still do not understand why some individuals do acquire and others do not acquire the infection
in the presence of the same risk factors. We do not understand why some individuals convert from latent to active
tuberculosis and why other individuals convert from active to inactive tuberculosis even without treatment.
As a matter of fact the immune system mounts a bouncing, robust and polyedral defence against Mycobacterium
tuberculosis, but the bacillus is so much artful and dextrous that it has ahead from this immunological fierce
accoutrements. Mycobacterium tuberculosis survival, multiplication, and transmission are largely favoured by the
immune mechanisms. The granuloma itself is more bacillus- than host-protective.
These abilities make Mycobacterium tuberculosis one of more successful human pathogens, but dumps in our
knowledge and the counterproductive immunity hinder development of new diagnostics, therapies and vaccines.
This occurs in front of an infection which engages one third of the world population and a disease which kills in a
year about 1.5 million individuals worldwide.
Understanding mechanisms and meaning of immune response in tuberculosis marks out the foundations of
strategies with a view to prepare effective vaccines and reliable diagnostic tools as well as to build up therapeutic
weapons. To gain these objectives is vital and urgent considering that tuberculosis is a common cause of
morbidity and is a leading cause of death.
Tuberculosis is a paradox disconcerting for immunologists
since a good immune response is developed in most
individuals, but this response does not just eliminate the
infection. On the contrary it aids the survival of Mycobac-
terium tuberculosis, assists its replication and transmission
and induces the bacterium to adopt a silent underhand
state from which it can reactivate as it pleases [1-4].
In addition, we would like to understand why some
individuals do acquire whilst others do not acquire the
infection (exposure conditions being equal), why some
rare individuals get rid of infection, and how some indi-
viduals (without any treatment) are able to convert an
active into an inactive infection [5].
In spite of innate immunity, mycobacteria
organize their bridgehead
Paraphrasing a famous aphorism of general Erwin
Rommel, with regard to the amphibious warfare, but
well appropriate in the contest of tuberculosis, all is
decided the first day, which gets the longest day.
Sometimes, soon after inhalation of Mycobacterium
tuberculosis, bacilli are phagocitized by alveolar macro-
phages which can kill them and settle the case. This prob-
ably depends the coincidence of lucky factors including an
intrinsic capacity of macrophages to generate reactive oxy-
gen intermediates (ROI) and consequent microbicidal
activity, a favorable inflammatory environment at the
infection site, and not outstanding pathogenetic abilities of
the inhaled strain [4].
If bacilli survive during the longest day (this is the
commonest occurrence) they have won the fight. They
proliferate at a logarithmic rate within dendritic cells
and alveolar macrophages inducing the production of
proinflammatory cytokines including interleukin (IL)-
1-a, IL-1b, tumor necrosis factor Ianus Bifrons, IL-6,
IL-12, and interferon (IFN)-g [2-4].
The role of these cytokines calls to mind the myth of
Ianus bifrons: IFN-g regulates T-cell response to mycobac-
terial infection, promotes antigen presentation, activates
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phagocytosis, production of ROI, TNF-a mediates early
inflammatory responses against infectious agents also
stimulating IL-1 and IL-6 production. The susceptibility to
mycobacterial infection of TNF-a deficient the mice
(which is unable to undertake the formation of granuloma:
but, it desirable or not? See afterwards), the increased
susceptibility to bacillus of Calmette and Guérin (BCG;
formerly vaccin Bilié de Calmette et Guérin) infection in
mice who received anti-TNF-a antibodies and the myco-
bacterial susceptibility of human treated with TNF-a
blockers should suggests its protective role. Also IL-6 is
fundamental in developing the early inflammatory
response. Its absence in mice may inhibit the maintenance
of the protective (may be) IL-17 and causes a delayed IFN-
g production and consequently determines an increased
mycobacterial burden. It is well known that IL-12
promotes the TH-1 response and that its deficiency is
associated in humans with an increased susceptibility to
mycobacterial infection [3,4,6,7]
This first immune mechanism is largely mediated by
molecules of the innate immunity. A large number of
them are involved, including multiple pattern recognition
receptors (that is toll-like receptors), C-type lectin receptor
family, cytosolic pattern-recognition receptors, pyrin
domain containing 3, and nucleotide-binding oligomeriza-
tion domain protein 2. These molecules recognize as
many again a number of mycobacterial products such as
lipoproteins, lipomannans, and DNA [8-12].
The main consequence of recognition of mycobacterial
molecules by innate immunity molecules is not only the
expression of pro-inflammatory cytokines, but also the
expression of cellular adhesion molecules and chemokines
which mobilize and activate macrophages, dendritic cells,
and neutrophils [11].
In many other infectious diseases this activity should
be considered commendable and useful [1]. Instead, in
tuberculosis, the inflow of these phagocytic cells supplies
a lot of cellular niches that allow the mycobacteria to
grow without hindrance [1,13,14]. The mycobacterial
population grow and spread to freshly recruited adjacent
uninfected cells. This is preceded (admirable strategy) by
a prolonged survival of the infected cell caused by the
Mycobacterium tuberculosis itself. In fact, Mycobacter-
ium tuberculosis inhibits the cell apoptosis also allowing
a larger number of bacteria are accumulated before
bacteria go out of the dead cell [15]. By means of this
mechanisms, the induction of the adaptive immunity is
delayed [15]. Also cell death is regulated by the Myco-
bacterium of ttuberculosis. In fact, the virulence factor
ESX1 type VII secretion system allow the bacteria to
induce cell death, allowing them a well-timed exit [16].
It is well known that Mycobacterium bovis (used in the
BCG vaccine) is devoid of the ESX1 type VII secretion
system [17].
In few words: during this first stage of the immune
response managed by the innate immunity, the Myco-
bacterium tuberculosis overcomes in big styles.
The armed equilibrium during the adaptive
immunity phase
Whereas the adaptive immunity to influenza virus is
recruited after 20 hours, innate immunity against tubercu-
lar infection is activated after more than a 40 days. Likely,
this delay is due to the delayed transport by dendritic cells
of live mycobacteria from the lungs to the draining
lymphonodes [1,18]. This delayed transport is caused by
the inhibition of transport (which should be stimulated by
ligands for the CC-chemokine receptor 7) mediated
by Mycobacterium tuberculosis [18]. The activation of the
adaptive immunity, with an accumulation of effector CD4+
and CD8+ T-cells in the lungs, open a period of trench
warfare during which the bacterial load remains stable.
Thus the adaptive immunity is not able to eliminate the
infection but not even to reduce its entity. Since during
this period of apparent immunological equilibrium myco-
bacteria accumulate mutations and a subset of bacteria
insist to replicate [1].
Some of the mechanisms which cause this defeat are
proper to immune cells and include expansion of Foxp3-
expressing regulatory T-cells, defective antigen recogni-
tion, and reduced macrophage major histocompatibility
complex expression and antigen processing [19]. Other
mechanisms are proper to the Mycobacterium tuberculosis
and include the resistance to the activation of macrophage
function mediated by IFN-g and blinding of specific CD4+
T-cell receptors caused by the downregulation of some
genes which determine the vanishing of sensible microbial
antigens. During this period, nitric oxide, carbon monox-
ide, and hypoxia predominate in the infection microenvir-
onment causing the expression of a regulon (controlled
by the signal transduction system DosR-DosS) which
allows Mycobacteria use lipids as an alternative energy
source [20].
During the adaptive immunity phase phase, a balance
between TH1 (and consequent IFN-g production) and
TH17 (and consequent IL-17 production which causes
neutrophil recruitment and tissue damage) cells can con-
trol bacterial growth and limit immunopathology [21].
During this phase gδ T-cells play a significant defensive
role [22]. Mycobacterium tuberculosis activate gδ T-cells
but also infected monocytes are efficient accessory cells
for gδ T-cells in a non-major histocompatibility complex-
restricted also by means of IL-15. Analogously to abT-cell
receptor+, gδ T-cells optimize their function interacting
with adhesion molecules and other molecules including
CD40-CD40L, CD28-B7.1/7.2. gδ T-cells produce both
TNF-a and IFN-g. Release of IFN-g is more efficient that
that from CD4+ T-cells.
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During this second phase, Mycobacteria do not gain
ground, but gain a crucial strategic victory: they preserve
and reinforce their bridgehead. Thus far the infected
subject has the latent tuberculosis. One third of the
world’s population have been infected with Mycobacterium
tuberculosis and have this form of tuberculosis [23].
The attack: from latent to active tuberculosis
At the right moment (right by the point of view of
Mycobacterium tuberculosis) the resuscitation-promoting
factor may be activated, even years and years after initial
infection, resuscitating bacteria from the nutrient-starved
state and determining the establishment of an active
symptomatic disease. Sometimes (especially in areas with a
high prevalence of infection) active disease is determined
by re-infection with a second strain. The latent infection
turn into an active infection. This change may be due to
mycobacteria as well as to the host [1].
Differently from viruses (which have fixed programs of
expression of their genes), mycobacteria are able to
change expression of their genes according to necessities
and stimuli which are derived from the environment.
Thus mycobacteria can change the expression of their
surface antigens and evade T-cell recognition. In mice
mycobacteria persist in the lungs also because, as soon
as CD4+ and CD8+ T-cells enter the lungs, ESAT6 and
Ag85B antigen expression is downregulated [24].
The host counterpart of re-activation may be an
immunological low on guard [25]. Mechanisms are
very poorly understood. Some model exist, including
anti-TNF monoclonal antibodies used in a number of
autoimmune disease, treatments with steroids, and the
CD4+ loss in patients with human immunodeficiency
virus-type 1 (HIV-1) infection . Interestingly, re-activation
in HIV-1 patients occurs largely before the nadir of CD4+
cells, because HIV-1 selectively eliminates Mycobacterium
tuberculosis antigen-specific CD4+ cells at a higher rate
than other antigen-specific CD4+ cells.
possible that this is a more general mechanism of T-
cell exhaustion in tuberculosis since the mycobacterial
load in the lungs is inversely related to the proportion
of blood antigen-specific T-cells. In addition, unfavour-
able polymorphisms of chemokines may alter the cell
trafficking in the lungs a reduce the recruitment of cells
which should contain the infection. It has been reported
that some patients with latent TB have signatures simi-
lar to those in patients with active TB. They manifest a
specific 86-transcript active TB. This signature is domi-
nated by a neutrophil-driven IFN-inducible gene profile,
consisting of both IFN-g and type I IFN-ab signalling
[26]. These findings underscore the role of IFNs and
neutrophils in the development of active tuberculosis
More vague are other possible mechanisms [1]. One is
the supposed longer delay in the development of adaptive
immunity (observed in the diabetic mice and possibly
caused by difficulties in the movement of dendritic cells
from the lungs to the lymph nodes) which could explain
the increased frequency of re-activation in the diabetic
patient. It is an old story that thinnish people (besides
their nutritional status) are more prone to tubercular
re-activation. This association may depend on leptin
which regulates, besides appetite, also growth and activity
of TH1 cells.
As a proof that this second stage of immune response
managed by adaptive immunity is a dynamic process of
shooting war, the patients may present fever and erythema
nodosum [27].
Only sometimes immunity holds on tightly
Even though the mechanisms are unexplored, it is known
that active infection is not a single track. In fact, a substan-
tial but anyway minority portion of patients with active
tuberculosis can succeed in getting rid of infection and
lead to an inactive tuberculosis. Whereas patients with
latent tuberculosis do not manifest chest-X-rays findings,
subjects with inactive tuberculosis have chest-X-rays
changes [1].
Memory T cells are distinguished by function and
migratory capacity. Central memory T-cells have high
proliferative activity and produce IL-2, whereas effector
memory T-cells produce bothIL-2 and IFN-g. Circulating
effector memory T-cells indicates that an antigen-specific
response persists, whereas circulating central memory
T-cells indicate that infection has been controlled [28].
Subjects with inactive tuberculosis evidence CD4+
central memory T-cell response. By contrast, patients
with active tuberculosis evidence CD4+ effector memory
T-cell responses [29].
Mycobacteria flood
The ultimate objective of all living beings is to disseminate
as much as possible their genetic stock. It could seem
unbelievable, but the adaptive immunity does favour the
transmission of mycobacteria [1].
For transmission mycobacteria need a large surface
exposed to the exterior. This surface allows the mycobac-
teria are expelled by an infected (and coughing) patient
with active tuberculosis, reach and infect a previously
uninfected individual [30,31]
A large surface is obtained by means the development of
cavitary tuberculosis which is the result of lung tissue
destruction. There are several lines of evidence, deriving
from the HIV-1 infection model, suggesting that T-cells
contribute to the development of cavitary tuberculosis: 1)
HIV-1 infected subjects less frequently have cavitary
tuberculosis; 2) HIV-1 infected patients less frequently
transmit mycobacteria as compared to HIV-1 uninfected
people; 3) in HIV-1 infected patients more the CD4+
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T-cells and more the frequency of cavitary tuberculosis.
Mechanisms are unknown. In very general terms it can be
supposed that T-cells promote a high level of inflamma-
tion which damage lung tissue [32].
As a matter of fact, strains of Mycobacterium tubercu-
losis diverged genetically many and many years ago (to
give an idea: during the upper paleolithic, roughly at the
end of the last ice age), but all strains have conserved
epitopes which are just that recognized by T-cells [33].
When something is preserved by a species for a long
time during evolution it means that it is fundamental
for survival of the species. From this we may conclude
that for Mycobacterium tuberculosis it is an evolutionary
advantage to be recognized by T-cells [34,35].
Granulomata: friend or foe?
Richard Morton descovered in 1679 granuloma (at the
time termed tubercles) and described it in his book
entitled Phthisiologia more than two centuries before
the discovery of the agent causing tuberculosis [36].
Epithelial granulomata are the hallmark of tuberculosis.
For a long time it has been believed that these evolutiona-
rily primitive structures control the infection since they
wall out bacilli. Unfortunately, it is not so [37-39].
An (apparently) hardened and dynamic arsenal of well
organized immunity cells is concentrated in tubercular
granulomata. T-cells, B-cells, neutrophils, fibroblasts,
macrophages (infected or uninfected), epithelioid cells
derived from macrophages, foamy macrophages, and mul-
tinucleated giant Langehans cells make up the tubercular
granulomata. Granulomata development starts shortly
after infection. At the beginning an innate granuloma
develops which is composed by neutrophils and alveolar
macrophages. Unfortunately, mycobacteria within granulo-
mata are able to disarm alveolar macrophages arresting
the phagolysosome fusion thus blocking the killing of
internalized mycobacteria. Mycobacteria also drive in
infected and harmless (by the point of view of mycobac-
teria) macrophages the production of chemoattractant
and pro-inflammatory cytokines. In addition, the relase by
mycobacteria of the 6 kDa early secretory antigenic target
causes the activation of the epithelium which stimulates
the recruitment of macrophages causing the expression of
matrix metalloproteinase-9 (MMP-9). Also the expression
of MMP-1 is driven by mycobacteria [40-42]
The result of this frantic fascination towards immune
cells is the development of the immune granuloma and
the multiplication of fresh pabulum for mycobacteria.
Mechanisms involved in the promotion and development
of granulomata are mostly driven by mycobacteria and
this clearly suggests that all is done in the mycobacteria’s
own interest [42].
TNF is believed to be fundamental for defence against
Mycobacteria and for granuloma formation. Howeever,
its iatrogenic inhibition disrupts granuloma allowing
replication of mycobacteria and thus increases the efficacy
of chemotherapics [43].
Thus, contrary to the traditional view of a protective role
of granulomata, it is now convincing that granulomata
favour the persistence and diffusion of the mycobacteriun
more than its segregation or even its elimination.
B-cells and antibodies: intelligence agents,
ancillary services, or useless?
The role of humoral immunity in tuberculosis is, at the
very least, evanescent. On the one hand there are the
inconsistent findings in studies of passive immunization,
the irrelevance of humoral deficiencies and B-cell immune
defects in Mycobacterium tuberculosis infection and dis-
ease and the ambiguous results in knockout mice besides
the general rule that antibodies are nearly ineffective
against intracellular agents [44-47].
On the other hand, there are well known exceptions to
this rule (infections caused by species of Leishmania,
Chlamydia, Francisella), the levels of specific antibodies
correlate to the efficacy of BCG vaccine, mice knockout
for polymeric immunoglobulin receptors have a higher
susceptibility to mycobacterial infections (is there a role of
mucosal dymeric IgA?), in animal models monoclonal
antibodies against mycobacterial antigens have a beneficial
effect in tuberculosis. In addition, there is evidence that B-
cells are a fundamental component of granulomata and
follicle-like B-cell aggregates (site of antigen presentation
to T-cells?) are a characteristic feature of granulomatous
progession in mycobacterial infection.
In a broader view it is well known that B-cells and
humoral immunity collaborate with T-cells and cellular
immunity in almost all infectious diseases and B-cells
act as antigen-presenting cells to T-cells.and/or polarize
T-cell activity influencing the production of cytokines.
B-cells are deeply involved in the production in the
lungs of the anti-inflammatory IL-10.
It is a peculiar finding that sometimes these mechan-
isms work in the presence of B-cells, but in the absence
of antibodies. Sometimes the opposite occurs. Even
more singularly, in tuberculosis and particularly in active
tuberculosis there is an significantly elevated prevalence
of subjects with autoantibodies [48].
Conclusions
Tuberculosis is a major international public health. Great
efforts are being made by science to oppose this plague.
But, candidly, translational results are still stalling.
Each human (and his/her immune mechanisms) is
very similar but also largely differ from other humans
(and their immune mechanisms). Maybe that persona-
lized medicine is the way to unravel the skein. Results
of how immune gene polymorphisms and, in particular,
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polymorphisms concerning how toll-like receptor and
autophagy-related genes influence tuberculosis susceptibil-
ity and clinical course are consistent with line of thinking
[49-51]. Maybe that some immunological dogma should
be revised. One of many is the ambiguous role of IFN-g
[52]. Maybe that some branch of research should be
implemented. One is that concerning the unaccountably
underestimated role of gδ T-cells [22]. Maybe that, if we
want to win the fight against Mycobacterium tuberculosis,
we must renounce to conformism. It is time for a different
way of thinking.
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